Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity
外源性受体介导环境对人类疾病和发病率的影响
基本信息
- 批准号:10194495
- 负责人:
- 金额:$ 87.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-01 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:Alcoholic Liver DiseasesAryl Hydrocarbon ReceptorBehaviorChemical ExposureChemicalsChronic DiseaseDiseaseEnvironmentEnvironmental Risk FactorEnzymesExposure toExtrahepaticFibrosisFreedomFunctional disorderFundingGene Expression RegulationGeneticGoalsGrantHealthHepaticHomeostasisHumanInterventionKnockout MiceLeadLigandsMediatingMediator of activation proteinMetabolic syndromeNational Institute of Environmental Health SciencesNuclear ReceptorsOutcomePathogenesisPathogenicityPathway interactionsPharmacologyPhysiologyPlayPopulationPrevention strategyPrincipal InvestigatorRegulationRiskRoleScientistSeminalSignal TransductionTestingTherapeuticTissuesToxicologyVisionXenobiotic MetabolismXenobioticsconstitutive androstane receptordesignenvironmental chemicalexperiencegene environment interactionhuman diseasehuman morbidityinsightknockout genenervous system disorderpregnane X receptorprogramsreceptortherapeutic targettherapy designtooltranscription factor
项目摘要
Title: Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity
Project Summary/Abstract:
This R35 proposal is designed to consolidate our current NIEHS funded projects into one program with the
focus on understanding the role of xenobiotic receptors in regulating the metabolism of xenobiotics and
endobiotics and the implications of this regulation in human health. The human population is at an increasing
risk of developing chronic diseases, such as fibrosis, metabolic syndrome, alcoholic liver disease, and
neurologic disorders. Environmental factors, including environmental chemicals, are among the major
contributing factors in the pathogenesis of these chronic diseases. As such, understanding the mechanisms
by which environmental chemicals modify human physiology and pathophysiology will help to design
therapeutic or preventive strategies to mitigate the pathogenic effect of environmental chemicals. Xenobiotic
receptors, including the xenobiotic nuclear receptors pregnane X receptor (PXR) and constitutive androstane
receptor (CAR) and the PAS domain transcriptional factor aryl hydrocarbon receptor (AHR), are best known for
their functions in sensing xenobiotic chemicals and regulating xenobiotic metabolism. Emerging evidence,
mainly through the creation and characterization of gene knockout mice and identification of endogenous
ligands, suggests that the xenobiotic receptors also have functions in regulating the homeostasis of
endobiotics and impacting pathophysiology. Our overarching hypothesis is that xenobiotic receptors are
critical environmental chemical-sensing transcriptional factors that mediate the environmental
chemical effects on human disease and morbidity. Mechanistically, xenobiotic receptors impact the
pathogenesis of human diseases by regulating the metabolism of xenobiotics and endobiotics in both
the hepatic and extrahepatic tissues. We propose that the xenobiotic receptors are pivotal environmental
modifiers that integrate signals from chemical exposures to the regulation of many aspects of human
physiology. To test our hypothesis, we will assemble a highly experienced team and employ a broad spectrum
of genetic and pharmacological tools, transdisciplinary approaches, and the expertise of an array of
collaborators and clinician scientists to comprehensively define the roles that xenobiotic receptors play in
environmentally influenced diseases, such as fibrosis, metabolic syndrome, alcoholic liver disease, and
neurologic disorders. By understanding these pathways, we cannot only understand the environment-gene
interactions and the implications of these interactions in human diseases, but also establish xenobiotic
receptors and their target enzymes and transporters as potential therapeutic targets to manage these human
diseases and morbidity. The insights gained from this R35 program can be used to design intervention
strategies to manipulate these pathways via therapeutics or to guide human behavior or the human
environment in a manner that is most beneficial to the sensitive populations. Over the next eight years, this
R35 program will give us the freedom and power to make considerable advances in our understanding of
xenobiotic receptors and how they influence human health. As the Principal Investigator, I am committed to
devote 55% of my total effort to this R35 program, and all of my existing NIEHS funding will be consolidated
into this grant if funded. I am confident that I can lead this R35 program, because I have studied xenobiotic
receptors for two decades and have demonstrated a broad vision and made seminal contributions to our
understanding of the toxicological and pathophysiological functions of xenobiotic receptors.
异生素受体介导环境对人类疾病的影响
项目概要/摘要:
这个R35提案旨在将我们目前的NIEHS资助项目合并为一个计划,
侧重于了解外源性受体在调节外源性物质代谢中的作用,
益生菌和这种调节对人类健康的影响。人类人口正在不断增长
患慢性疾病的风险,如纤维化、代谢综合征、酒精性肝病,以及
神经系统疾病环境因素,包括环境化学品,是主要的
这些慢性疾病的发病机制中的促成因素。因此,了解这些机制
环境化学物质改变人类生理和病理生理的机制将有助于设计
减轻环境化学品致病作用的治疗或预防策略。Xenobiotic
受体,包括异生物质核受体-雄烷X受体(PXR)和组成型雄烷
受体(CAR)和PAS结构域转录因子芳烃受体(AHR),最为人所知的是
它们在感受异生物化学物质和调节异生物代谢方面的功能。新出现的证据,
主要通过基因敲除小鼠的创建和表征以及内源性
配体,表明异生素受体也具有调节体内平衡的功能,
内生菌和影响病理生理学。我们的首要假设是,异生物素受体是
关键的环境化学传感转录因子介导的环境
对人类疾病和发病率的化学影响。从机制上讲,外源性受体影响
人类疾病的发病机制,通过调节代谢的外源性物质和内源性物质,在这两个
肝组织和肝外组织。我们认为,外源性受体是关键的环境
修饰剂整合了来自化学暴露的信号,以调节人体的许多方面,
physiology.为了验证我们的假设,我们将组建一支经验丰富的团队,
遗传和药理学工具,跨学科方法,以及一系列
合作者和临床科学家全面定义的作用,异生素受体发挥,
环境影响的疾病,如纤维化、代谢综合征、酒精性肝病,以及
神经系统疾病通过了解这些途径,我们不仅可以了解环境-基因
相互作用和这些相互作用在人类疾病中的影响,而且还建立了异生素
受体及其靶酶和转运蛋白作为潜在的治疗靶点来管理这些人
疾病和发病率。从R35项目中获得的见解可用于设计干预措施
通过治疗或指导人类行为或人类行为来操纵这些途径的策略
以最有利于敏感人群的方式保护环境。在接下来的八年里,
R35计划将给我们自由和力量,使我们在理解方面取得相当大的进步。
异生物素受体及其对人类健康的影响。作为首席研究员,我致力于
我将全部精力的55%投入到R35计划中,我现有的NIEHS资金将被合并
如果获得资助,将转入这笔赠款。我有信心我可以领导这个R35项目,因为我研究过异生物质,
二十年来,他展示了广阔的视野,并为我们的研究做出了开创性的贡献。
了解异生物质受体的毒理学和病理生理学功能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Wen Xie其他文献
Wen Xie的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Wen Xie', 18)}}的其他基金
Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity
外源性受体介导环境对人类疾病和发病率的影响
- 批准号:
10411925 - 财政年份:2019
- 资助金额:
$ 87.56万 - 项目类别:
PXR-Mediated Xenobiotic Response in the Pathogenesis Hemorrhagic Shock
失血性休克发病机制中 PXR 介导的异生素反应
- 批准号:
10302289 - 财政年份:2019
- 资助金额:
$ 87.56万 - 项目类别:
Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity
外源性受体介导环境对人类疾病和发病率的影响
- 批准号:
10623308 - 财政年份:2019
- 资助金额:
$ 87.56万 - 项目类别:
The hepatic function of cholesterol sulfotransferase 2B1b (SULT2B1b)in energy met
胆固醇磺基转移酶2B1b(SULT2B1b)在能量代谢中的肝功能
- 批准号:
8754531 - 财政年份:2014
- 资助金额:
$ 87.56万 - 项目类别:
The hepatic function of cholesterol sulfotransferase 2B1b (SULT2B1b)in energy met
胆固醇磺基转移酶2B1b(SULT2B1b)在能量代谢中的肝功能
- 批准号:
9087207 - 财政年份:2014
- 资助金额:
$ 87.56万 - 项目类别:
A Novel Regulation of the Phase II Enzyme Estrogen Sulfotransferase
II 期酶雌激素磺基转移酶的新调控
- 批准号:
8895932 - 财政年份:2014
- 资助金额:
$ 87.56万 - 项目类别:
A Novel Regulation of the Phase II Enzyme Estrogen Sulfotransferase
II 期酶雌激素磺基转移酶的新调控
- 批准号:
9265092 - 财政年份:2014
- 资助金额:
$ 87.56万 - 项目类别:
A Novel Regulation of the Phase II Enzyme Estrogen Sulfotransferase
II 期酶雌激素磺基转移酶的新调控
- 批准号:
9060933 - 财政年份:2014
- 资助金额:
$ 87.56万 - 项目类别:
The Perinatal Pharmacology of the Nuclear Receptor
核受体的围产期药理学
- 批准号:
8628853 - 财政年份:2013
- 资助金额:
$ 87.56万 - 项目类别:
The Perinatal Pharmacology of the Nuclear Receptor
核受体的围产期药理学
- 批准号:
9043915 - 财政年份:2013
- 资助金额:
$ 87.56万 - 项目类别:
相似海外基金
The Role of CD96hi Cells Mediated by Transcription Factor Aryl Hydrocarbon Receptor (AHR) in HIV Pathogenesis.
转录因子芳基烃受体 (AHR) 介导的 CD96hi 细胞在 HIV 发病机制中的作用。
- 批准号:
502605 - 财政年份:2024
- 资助金额:
$ 87.56万 - 项目类别:
Understanding the origins and mechanisms of aryl hydrocarbon receptor promiscuity
了解芳烃受体混杂的起源和机制
- 批准号:
10679532 - 财政年份:2023
- 资助金额:
$ 87.56万 - 项目类别:
Decoding how the aryl hydrocarbon receptor (AhR) controls cigarette smoke-induced lung inflammation and development of chronic obstructive pulmonary disease (COPD)
解读芳烃受体 (AhR) 如何控制香烟烟雾引起的肺部炎症和慢性阻塞性肺病 (COPD) 的发展
- 批准号:
487508 - 财政年份:2023
- 资助金额:
$ 87.56万 - 项目类别:
Operating Grants
Identification of Aryl Hydrocarbon Receptor as a Novel Druggable Modulator of HIV-1 Latency
鉴定芳基烃受体作为 HIV-1 潜伏期的新型药物调节剂
- 批准号:
493698 - 财政年份:2023
- 资助金额:
$ 87.56万 - 项目类别:
Operating Grants
Elucidation of the essential mechanism of action of aryl hydrocarbon receptor agonists on breast cancer cells
阐明芳烃受体激动剂对乳腺癌细胞作用的基本机制
- 批准号:
23K14396 - 财政年份:2023
- 资助金额:
$ 87.56万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Regulation of long-noncoding RNA (lncRNA) by the aryl hydrocarbon receptor
芳烃受体对长链非编码 RNA (lncRNA) 的调节
- 批准号:
RGPIN-2020-04462 - 财政年份:2022
- 资助金额:
$ 87.56万 - 项目类别:
Discovery Grants Program - Individual
The aryl hydrocarbon receptor (AhR) controls myofibroblast differentiation via lncRNA
芳烃受体 (AhR) 通过 lncRNA 控制肌成纤维细胞分化
- 批准号:
573498-2022 - 财政年份:2022
- 资助金额:
$ 87.56万 - 项目类别:
University Undergraduate Student Research Awards
Hepatic Aryl Hydrocarbon Receptor Regulation of Obesity: Mechanisms of Action
肝芳基烃受体对肥胖的调节:作用机制
- 批准号:
10701901 - 财政年份:2022
- 资助金额:
$ 87.56万 - 项目类别:
The impact of Aryl hydrocarbon receptor signaling on Toll like receptor-mediated inflammation
芳基碳氢化合物受体信号传导对 Toll 样受体介导的炎症的影响
- 批准号:
10569113 - 财政年份:2022
- 资助金额:
$ 87.56万 - 项目类别:
The impact of Aryl hydrocarbon receptor signaling on Toll like receptor-mediated inflammation
芳基碳氢化合物受体信号传导对 Toll 样受体介导的炎症的影响
- 批准号:
10367788 - 财政年份:2022
- 资助金额:
$ 87.56万 - 项目类别: